Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

The Knee Injury Cohort at the Kennedy (KICK) study has completed a significant milestone this week with the recruitment of all required participants – 150 individuals aged between 18 and 50 with recent knee injuries.

After a joint injury, around 50% of people will go on to develop premature osteoarthritis. Chief investigator Dr Fiona Watt says: “Following the 150 participants in KICK over the next five years will help us to understand why a joint injury leads to osteoarthritis in some individuals, but not others. This will allow us to develop tests which identify those at greatest risk. We hope that this will ultimately enable us to intervene in key pathways following a joint injury to prevent this disabling condition”.

Other work in the Kennedy Institute has identified specific markers of inflammation following injury; KICK aims to determine whether it is possible to predict the development of osteoarthritis from this initial molecular response of the joint to the injury. The study also hopes to identify novel targets for preventing or treating early disease.

KICK is run at The Arthritis Research UK Centre for Osteoarthritis Pathogenesis, based in the Kennedy Institute of Rheumatology, at Oxford, and benefits from a range of collaborations, namely with Andrew Williams, leading UK sports knee surgeon working at Fortius Clinic, London. Commenting on the recent milestone, he said: “This is a great achievement. Understanding the key detrimental humoral 'players' that lead to osteoarthritis will open the possibility of providing therapies to prevent development of osteoarthritis after trauma which is especially prevalent in the young and increasingly so. The need for this is one of the most pressing goals in medicine today.”

KICK is funded by the Kennedy Trust for Rheumatology Research, with additional infrastructure support from Arthritis Research UK.

Similar stories

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity